GLP-1RA and DPP-4 inhibitors are useful in the management of patients with T2DM over the spectrum of HbA1c levels, including drug naïve patients as well as those treated with other glucose lowering therapies. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.